TISIDB

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF06741 LsmAD domain PF07145 Ataxin-2 C-terminal region PF14438 Ataxin 2 SM domain
Function	Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane.

> Gene Ontology [ TOP ]
Biological Process	GO:0002090 regulation of receptor internalization GO:0002091 negative regulation of receptor internalization GO:0006403 RNA localization GO:0006417 regulation of translation GO:0006898 receptor-mediated endocytosis GO:0010603 regulation of cytoplasmic mRNA processing body assembly GO:0010608 posttranscriptional regulation of gene expression GO:0015931 nucleobase-containing compound transport GO:0022613 ribonucleoprotein complex biogenesis GO:0022618 ribonucleoprotein complex assembly GO:0030100 regulation of endocytosis GO:0031623 receptor internalization GO:0033962 cytoplasmic mRNA processing body assembly GO:0034063 stress granule assembly GO:0034248 regulation of cellular amide metabolic process GO:0043112 receptor metabolic process GO:0045806 negative regulation of endocytosis GO:0048259 regulation of receptor-mediated endocytosis GO:0048261 negative regulation of receptor-mediated endocytosis GO:0050657 nucleic acid transport GO:0050658 RNA transport GO:0051051 negative regulation of transport GO:0051236 establishment of RNA localization GO:0060627 regulation of vesicle-mediated transport GO:0071826 ribonucleoprotein complex subunit organization GO:1902115 regulation of organelle assembly
Molecular Function	GO:0005154 epidermal growth factor receptor binding GO:0008022 protein C-terminus binding GO:0070851 growth factor receptor binding
Cellular Component	GO:0005802 trans-Golgi network GO:0005844 polysome GO:0010494 cytoplasmic stress granule GO:0031984 organelle subcompartment GO:0035770 ribonucleoprotein granule GO:0036464 cytoplasmic ribonucleoprotein granule GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ATXN2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ATXN2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ATXN2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.013	0.953
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.209	0.883
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.174	0.867
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.289	0.266
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.317	0.894
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.259	0.935
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.066	0.843
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.083	0.954
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.028	0.986
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.19	0.877
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.686	0.692
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.083	0.124

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ATXN2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	0	14.8	0.00448
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	0	14.8	0.00826
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	0	10.5	0.135
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	0	12.5	0.485
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ATXN2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ATXN2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ATXN2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ATXN2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ATXN2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ATXN2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ATXN2
Name	ataxin 2
Aliases	ATX2; trinucleotide repeat containing 13; TNRC13; spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, a ......
Chromosomal Location	12q23-q24.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ATXN2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ATXN2